Inherited ion channel diseases: a brief review.

Ion channelopathies are diseases caused by dysfunctional ion channels that may lead to sudden death. These diseases can be either acquired or inherited. The main phenotypes observed in patients carrying these heritable arrhythmia syndromes are congenital long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. In the recent years, tremendous progress has been made in the recognition, mechanisms, and treatment of these diseases. The goal of this review is to provide an overview of the main phenotypes, genetic underpinnings, risk stratification, and treatment options for these so-called cardiac ion channelopathies.

[1]  A. J. Williams,et al.  The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. , 2015, Circulation research.

[2]  A. Wilde,et al.  Genetic and clinical advances in congenital long QT syndrome. , 2014, Circulation Journal.

[3]  A. Moss,et al.  Efficacy of different beta-blockers in the treatment of long QT syndrome. , 2014, Journal of the American College of Cardiology.

[4]  Wataru Shimizu,et al.  Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes , 2013, Heart rhythm.

[5]  Hanno L. Tan,et al.  Yield of Molecular and Clinical Testing for Arrhythmia Syndromes: Report of 15 Years’ Experience , 2013, Circulation.

[6]  Dan M Roden,et al.  Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death , 2013, Nature Genetics.

[7]  R. Hauer,et al.  Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. , 2012, Journal of the American College of Cardiology.

[8]  P. Schwartz,et al.  Spectrum and Prevalence of Mutations Involving Brs1-through Brs12-susceptibility Genes in a Cohort of Unrelated Patients Referred for Brugada Syndrome Genetic Testing Implications for Genetic Testing , 2022 .

[9]  Michael Christiansen,et al.  Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death. , 2012, American journal of human genetics.

[10]  W. Shimizu,et al.  Seasonal and circadian distributions of cardiac events in genotyped patients with congenital long QT syndrome. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[11]  A. Wilde,et al.  Familial Evaluation in Catecholaminergic Polymorphic Ventricular Tachycardia: Disease Penetrance and Expression in Cardiac Ryanodine Receptor Mutation–Carrying Relatives , 2012, Circulation. Arrhythmia and electrophysiology.

[12]  D. Tester,et al.  Cardiac channel molecular autopsy: insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. , 2012, Mayo Clinic proceedings.

[13]  E. Kaufman,et al.  Mutations in Cytoplasmic Loops of the KCNQ1 Channel and the Risk of Life-Threatening Events: Implications for Mutation-Specific Response to &bgr;-Blocker Therapy in Type 1 Long-QT Syndrome , 2012, Circulation.

[14]  A. Leenhardt,et al.  Absence of triadin, a protein of the calcium release complex, is responsible for cardiac arrhythmia with sudden death in human , 2012, Human molecular genetics.

[15]  Prashanthan Sanders,et al.  Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. , 2012, Heart rhythm.

[16]  A. Zwinderman,et al.  Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  P. Schwartz,et al.  QTc behavior during exercise and genetic testing for the long-QT syndrome. , 2011, Circulation.

[18]  A. Wilde,et al.  Rebuttal to EP testing predicts cardiac events in patients with Brugada syndrome. , 2011, Heart rhythm.

[19]  Michael J Ackerman,et al.  Mutation and gender-specific risk in type 2 long QT syndrome: implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome. , 2011, Heart rhythm.

[20]  J. Brugada,et al.  Electrophysiologic testing predicts events in Brugada syndrome patients. , 2011, Heart rhythm.

[21]  Charles Antzelevitch,et al.  Electrophysiologic basis for the antiarrhythmic actions of ranolazine. , 2011, Heart rhythm.

[22]  A. Wilde,et al.  Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. , 2011, Journal of the American College of Cardiology.

[23]  C. Antzelevitch,et al.  Short QT Syndrome: From Bench to Bedside , 2010, Circulation. Arrhythmia and electrophysiology.

[24]  M Borggrefe,et al.  Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome: Results From the FINGER Brugada Syndrome Registry , 2010, Circulation.

[25]  J. Towbin,et al.  An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. , 2010, Heart rhythm.

[26]  Michael J Ackerman,et al.  Genotype-phenotype aspects of type 2 long QT syndrome. , 2009, Journal of the American College of Cardiology.

[27]  Fabio Mosca,et al.  Prevalence of the Congenital Long-QT Syndrome , 2009, Circulation.

[28]  S. Priori,et al.  Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). , 2009, Heart rhythm.

[29]  A. Leenhardt,et al.  Incidence and Risk Factors of Arrhythmic Events in Catecholaminergic Polymorphic Ventricular Tachycardia , 2009, Circulation.

[30]  D. Roden,et al.  Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans , 2009, Nature Medicine.

[31]  W. Shimizu,et al.  Seasonal and circadian distributions of ventricular fibrillation in patients with Brugada syndrome. , 2008, Heart rhythm.

[32]  Tohru Ohe,et al.  Fragmented QRS as a Marker of Conduction Abnormality and a Predictor of Prognosis of Brugada Syndrome , 2008, Circulation.

[33]  A. Wilde,et al.  Fever increases the risk for cardiac arrest in the Brugada syndrome. , 2008, Annals of internal medicine.

[34]  P. Schwartz,et al.  Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. , 2008, The New England journal of medicine.

[35]  A. Wilde,et al.  Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. , 2008, Trends in cardiovascular medicine.

[36]  S. Priori,et al.  Gating Properties of SCN5A Mutations and the Response to Mexiletine in Long-QT Syndrome Type 3 Patients , 2007, Circulation.

[37]  A. Krahn,et al.  Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. , 2006, Heart rhythm.

[38]  Michel Haissaguerre,et al.  Short QT syndrome: clinical findings and diagnostic-therapeutic implications. , 2006, European heart journal.

[39]  J. A. Gomes,et al.  Risk Stratification of Individuals with the Brugada Electrocardiogram: A Meta‐Analysis , 2006, Journal of cardiovascular electrophysiology.

[40]  D. Tester,et al.  Effect of clinical phenotype on yield of long QT syndrome genetic testing. , 2006, Journal of the American College of Cardiology.

[41]  S. Priori,et al.  A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene , 2005, Circulation research.

[42]  Wataru Shimizu,et al.  Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.

[43]  I. Gussak,et al.  Short QT syndrome: mechanisms, diagnosis and treatment , 2005, Nature Clinical Practice Cardiovascular Medicine.

[44]  S. Priori,et al.  Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. , 2004, JAMA.

[45]  S. Priori,et al.  Association of Long QT Syndrome Loci and Cardiac Events Among Patients Treated With β-Blockers , 2004 .

[46]  A. V. van Ginneken,et al.  Mutation in the KCNQ1 Gene Leading to the Short QT-Interval Syndrome , 2004, Circulation.

[47]  M. Ackerman,et al.  Cardiac channelopathies: it's in the genes , 2004, Nature Medicine.

[48]  Michel Haissaguerre,et al.  Short QT syndrome: pharmacological treatment. , 2004, Journal of the American College of Cardiology.

[49]  S. Priori,et al.  Left Cardiac Sympathetic Denervation in the Management of High-Risk Patients Affected by the Long-QT Syndrome , 2004, Circulation.

[50]  J. Juang,et al.  Brugada Syndrome – An Under-Recognized Electrical Disease in Patients with Sudden Cardiac Death , 2004, Cardiology.

[51]  J. Brugada,et al.  Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.

[52]  Calum A MacRae,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[53]  Carlo Napolitano,et al.  Clinical and Molecular Characterization of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia , 2002, Circulation.

[54]  D. Lancet,et al.  A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. , 2001, Cold Spring Harbor symposia on quantitative biology.

[55]  G. Breithardt,et al.  Life-threatening Arrhythmias Genotype-phenotype Correlation in the Long-qt Syndrome : Gene-specific Triggers for Genotype-phenotype Correlation in the Long-qt Syndrome Gene-specific Triggers for Life-threatening Arrhythmias , 2022 .

[56]  D. Lancet,et al.  A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. , 2001, American journal of human genetics.

[57]  R. Hauer,et al.  Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). , 1999, Journal of the American College of Cardiology.

[58]  W. Allan,et al.  Long QT Syndrome , 1998, Pediatrics.

[59]  G. Breithardt,et al.  Genetic basis and molecular mechanism for idiopathic ventricular fibrillation , 1998, Nature.

[60]  G. Breithardt,et al.  KCNE1 mutations cause Jervell and Lange-Nielsen syndrome , 1997, Nature Genetics.

[61]  M. Keating,et al.  Molecular basis of the long-QT syndrome associated with deafness. , 1997, The New England journal of medicine.

[62]  A. Moss,et al.  ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. , 1995, Circulation.

[63]  P. Coumel,et al.  Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. , 1995, Circulation.

[64]  J. Brugada,et al.  Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. , 1992, Journal of the American College of Cardiology.

[65]  A. Moss,et al.  The Long QT Syndrome: Prospective Longitudinal Study of 328 Families , 1991, Circulation.